ORM 1 As a Biomarker of Increased Vascular Invasion and Decreased Sorafenib Sensitivity in Hepatocellular Carcinoma. Biomol Biomed 2022, 22 (6), 949-958. https://doi.org/10.17305/bjbms.2022.7268.